Valproic acid
- Generic Name
- Valproic acid
- Brand Names
- Depakene, Depakote, Epival
- Drug Type
- Small Molecule
- Chemical Formula
- C8H16O2
- CAS Number
- 99-66-1
- Unique Ingredient Identifier
- 614OI1Z5WI
- Background
Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects o...
- Indication
Indicated for:
1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures.
2) Adjunctive therapy in the management of multiple seizure types that include absence seizures.
3) Prophylaxis of migraine headaches.
4) Acute management of mania associated with bipolar disorder.
...
- Associated Conditions
- Bipolar Disorder (BD), Complex Partial Seizure Disorder, Depressive Episodes, Migraine, Petit Mal Epilepsy, Seizure, multiple types, Acute Manic episode
- Associated Therapies
- -
Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda - 2012
- Conditions
- Interventions
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Centers for Disease Control and Prevention
- Registration Number
- NCT01730313
- Locations
- 🇺🇬
Kitgum Nodding Syndrome Treatment Center, Kitgum General Hospital, Kitgum, Uganda
Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Gregory Jicha, 323-5550
- Target Recruit Count
- 14
- Registration Number
- NCT01729598
- Locations
- 🇺🇸
Sander's Brown Center on Aging, Lexington, Kentucky, United States
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 14
- Registration Number
- NCT01695122
- Locations
- 🇧🇷
Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, SP, Brazil
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 309
- Registration Number
- NCT01674010
- Locations
- 🇹🇷
Elan Investigational Site, Istanbul, Turkey
Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01622439
- Locations
- 🇸🇪
Skåne University Hospital, Dept. of Oncology, Lund, Sweden
Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 41
- Registration Number
- NCT01619644
- Locations
- 🇫🇷
University Hospital Bordeaux, France, Bordeaux, France
Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease
- Conditions
- Interventions
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 155
- Registration Number
- NCT01552434
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss
- Conditions
- Interventions
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01548066
- Locations
- 🇰🇷
Department of Dermatology, Seoul National University Hospital, Seoul, Korea, Republic of
Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Ewha Womans University
- Registration Number
- NCT01543139
- Locations
- 🇰🇷
Ewha Womans University Medical Center, Seoul, Korea, Republic of
A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01495104
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.